Open Access Repository

Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study

Downloads

Downloads per month over past year

Khalafallah, AA, Slancar, M, Cosolo, W, Abdi, E, Chern, B, Woodfield, RJ and Copeman, MC 2017 , 'Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study' , European Journal of Cancer Care , pp. 1-9 , doi: 10.1111/ecc.12638.

[img]
Preview
PDF
115414 Journal ...pdf | Download (236kB)

| Preview

Abstract

Malignant bone disease can cause significant morbidity. Monthly zoledronic acid (ZOL) reduces skeletal complications; however, limited data are available regarding long-term safety. We aimed to assess efficacy and safety of ZOL beyond 1 year of treatment. We prospectively evaluated 73 patients; breast cancer (n = 29), castrate-resistant prostate cancer (n = 13), multiple myeloma (n = 31) from 2006 to 2008 in 19 cancer centres. All patients were diagnosed with bone disease and had completed 1-2 years of monthly ZOL (4 mg) and received a further 1-2 years of therapy following contemporary guidelines for managing risks of osteonecrosis of the jaw (ONJ) and renal toxicity. Overall rates of skeletal-related events (SREs), renal impairment and ONJ were assessed. Over the additional 1 year of treatment, only 5.5% (n = 4) of patients developed a new SRE. The overall Kaplan-Meier estimate for SRE incidence after 48 weeks on study was 6.75% (95 CI: 2.5-17.3). Although 51% of patients reported serious adverse events, only two cases were suspected as ZOL related. No patients had confirmed ONJ. The observed incidence of new renal impairment was 11% (none due to ZOL). Our study confirms the benefit over risk of continuing monthly ZOL for at least 2 years in patients with advanced cancer involving bone.

Item Type: Article
Authors/Creators:Khalafallah, AA and Slancar, M and Cosolo, W and Abdi, E and Chern, B and Woodfield, RJ and Copeman, MC
Keywords: bone metastasis, long-term safety, osteonecrosis of the jaw, renal impairment, zoledronic acid
Journal or Publication Title: European Journal of Cancer Care
Publisher: Blackwell Publishing Ltd
ISSN: 0961-5423
DOI / ID Number: 10.1111/ecc.12638
Copyright Information:

Copyright 2017 The AuthorsLicensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)https://creativecommons.org/licenses/by-nc-nd/4.0/

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP